Published Research and Presentations

Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [ 177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

TheraP

03/06/2024

Edmond M. Kwan, Michael S. Hofman, Sarah W.S. Ng, Louise Emmett, Shahneen Sandhu, James P. Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew J. Marting,j, Martin R. Stockler, Grainne Donnellan, Matti Annala, Sofie H. Tolmeijer, Arun A. Azad, Ian D. Davis,, Alexander W. Wyatt

PSA at 7 months is prognostic in metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide: landmark analysis of ENZAMET (ANZUP 1304)

ENZAMET

03/06/2024

Ronan A. McLaughlin, Hayley Thomas, Ian D. Davis, Robert R. Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume8, David W. Pook Francis Parnis, Scott A. North, Gavin M. Marx, John McCaffrey, Raymond S. McDermott, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Christopher J. Sweeney

TRIALS IN PROGRESS -P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours

P3BEP

ASCO 2024

29/01/2024

B Mak, B Tran, AJ Martin, FD Pashankar, D Mazhar, RA Huddart, M Wheater, E Walpole, DR Feldman, E Dunwoodie, NJ Lawrence, AJ Birtle, D Wyld, AG Stevanovic, JM Balagtas, MR Stockler, PS Grimison, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): a retrospective analysis from the ENZAMET trial (ANZUP 1304)

ENZAMET

ASCO 2024

29/01/2024

Ian D. Davis, Andrew James Martin, Robert R. Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David W. Pook, Francis Parnis, Scott A. North, Gavin M. Marx, John McCaffrey, Raymond S. McDermott, Andrisha -Jade Inderjeeth, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Christopher J. Sweeney

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP 1303) and DASL-HiCaP(ANZUP 1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

DASL-HiCaP

ASCO 2024

29/01/2024

Tamim Niazi, Paul L. Nguyen, Scott Williams, Martin R. Stockler, Andrew J. Martin, Lisa Horvath, Hayley Thomas, Danka S. Zebic, Felicia Roncolato, Tee Lim, Chakiath Jose, Jarad Martin, Hans T. Chung, Annie Ebacher, Scott C. Morgan, Simon Hughes, Sean M. McBride, Paul J. Kelly, Ian D. Davis, Christopher J. Sweeney, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour following orchidectomy (ANZUP 1906)

CLIMATE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Jeremy Lewin, Aaron R. Hansen, Peter Grimison, James Lynam, Andrew Weickhardt, Phillip Parente, David Campbell, Wei Hong, Gavin Marx, Orlaith Heron, Ben Namdarian, Anna Kuchel, Margaret McJannett, Thomas Cusick, Antoinette Fontela, Sophie O’Haire, Kristina Zlatic, Ian D. Davis, and Ben Tran, on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.